Literature DB >> 28624960

Drug-Induced Pyoderma Gangrenosum: A Review.

Jane Y Wang1, Lars E French2, Neil H Shear3,4, Afkham Amiri5, Afsaneh Alavi6,7.   

Abstract

Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that may be caused by an adverse drug reaction. We discuss the clinical presentation and outcomes of 52 cases of drug-induced PG reported to date in the literature. We conducted our literature search for case reports of drug-induced PG using keywords on PubMed and Medical Subject Heading (MeSH) terms on MEDLINE and EMBASE. To assess the probability that each case of PG was related to drug therapy, we used the Naranjo criteria. We identified 44 studies in the literature, with a total of 52 cases of drug-induced PG. The mean Naranjo score for cocaine-induced PG (n = 13) was 9.4, indicating a definite adverse drug reaction, while the mean Naranjo scores for isotretinoin (n = 5), propylthiouracil (n = 5), and sunitinib (n = 5) were 6.2, 6.8, and 7.4, respectively, indicating probable adverse drug reactions. Drugs should be considered as a possible triggering event whenever PG is diagnosed, and clinicians should particularly consider this in patients taking isotretinoin, propylthiouracil, or sunitinib, as well as in patients with a history of cocaine use.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28624960     DOI: 10.1007/s40257-017-0308-7

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  8 in total

1.  A case of pyoderma gangrenosum induced by insulin.

Authors:  Malcom Noronha; Sukriti Arora; Kantilatha Pai; B Sathish Pai; Anuradha Jindal
Journal:  Int Wound J       Date:  2019-07-29       Impact factor: 3.315

2.  Epidemiology of pyoderma gangrenosum: Results from an Italian prospective multicentre study.

Authors:  Paola Monari; Ruggero Moro; Alberico Motolese; Cosimo Misciali; Carlotta Baraldi; Pier Alessandro Fanti; Stefano Caccavale; Mario Puviani; Daniela Olezzi; Pierfrancesco Zampieri; Giusto Trevisan; Katiuscia Nan; Chiara Fiorentini; Giovanni Pellacani; Giulio Gualdi
Journal:  Int Wound J       Date:  2018-06-06       Impact factor: 3.315

3.  Pyoderma gangrenosum - a guide to diagnosis and management .

Authors:  Christina George; Florence Deroide; Malcolm Rustin
Journal:  Clin Med (Lond)       Date:  2019-05       Impact factor: 2.659

Review 4.  Skin Manifestation Induced by Immune Checkpoint Inhibitors.

Authors:  Toshiyuki Yamamoto
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-05-10

Review 5.  Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab.

Authors:  Anastasia Skalkou; Sofia-Magdalini Manoli; Alexandros Sachinidis; Vasilios Ntouros; Konstantinos Petidis; Eleni Pagkopoulou; Efstratios Vakirlis; Athina Pyrpasopoulou; Theodoros Dimitroulas
Journal:  Rheumatol Int       Date:  2017-10-26       Impact factor: 2.631

6.  A case of rituximab-induced pyoderma gangrenosum.

Authors:  Jorge R Georgakopoulos; Gina Rohekar; Fiona E Lovegrove
Journal:  JAAD Case Rep       Date:  2018-10-29

7.  Cocaine/Levamisole-Induced, Skin-Limited ANCA-Associated Vasculitis with Pyoderma Gangrenosum-like Presentation.

Authors:  Mirjana Urosevic-Maiwald; Jan-Hendrik B Hardenberg; Jürg Hafner; Marie-Charlotte Brüggen
Journal:  Dermatopathology (Basel)       Date:  2022-06-29

Review 8.  Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review.

Authors:  Roberto Maglie; Giovanni Genovese; Farzan Solimani; Alba Guglielmo; Alessandro Pileri; Francesca Portelli; Michael Hertl; Angelo Valerio Marzano; Emiliano Antiga
Journal:  Am J Clin Dermatol       Date:  2020-12       Impact factor: 7.403

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.